January 16, 2023SHILAP Revista de lepidopterologíaOpen Access

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

View Full Paper

Ask AI

Bookmark

Why the study?

NAFLD has a complex pathogenesis and currently lacks specific drugs, with treatments primarily targeting pathogenic factors, key links of pathogenesis, and related metabolic disorders.

Design

Review article

Authors

RLRong LiThe Affiliated Yongchuan Hospital of Chongqing Medical University JZJunyan ZouChinese PLA General Hospital WRWei RanFirst Affiliated Hospital of Guangzhou Medical University

Discussion

Member takes

Implication

NAFLD still lacks approved specific pharmacotherapies; leaves open validation of metabolic, anti-inflammatory, and enterohepatic agents in prospective trials.

Structured PICO

Population

Patients with non-alcoholic fatty liver disease (NAFLD) or metabolic (dysfunction) associated with fatty liver disease (MAFLD)

Intervention

NAFLD treatments including diet, lifestyle changes, and drug therapies targeting glucose and lipid metabolism, anti-inflammation, and the enterohepatic axis

This review provides a comprehensive overview of current and emerging treatment strategies for NAFLD/MAFLD, emphasizing the shift towards targeting metabolic pathways and the gut microbiota.

Cite This Study

Li et al. (2023) studied this question.

synapsesocial.com/papers/69deefca92a5e9426ae93e45 https://doi.org/10.3389/fendo.2022.1087260

View Full Paper

Ask AI

Bookmark

Implication

NAFLD still lacks approved specific pharmacotherapies; leaves open validation of metabolic, anti-inflammatory, and enterohepatic agents in prospective trials.

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider